Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 11/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8093410 | 0.79 | SLC18A3 (0.58) | SLC18A3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10138882 | 0.78 | HRH3 (0.64) | — | |
| SCHEMBL13103513 | 0.77 | HRH3 (0.69) | — | |
| SCHEMBL1506940 | 0.75 | HRH3 (0.43) | KDM2BLMNA | |
| SCHEMBL599676 | 0.75 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL599543 | 0.75 | HRH3 (0.55) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL12031777 | 0.74 | SLC18A3 (1.00) | SLC18A3 | |
| Oxalic Acid SCHEMBL9980613 | 0.74 | SLC18A3 (0.94) | SLC18A3 | |
| SCHEMBL9980653 | 0.73 | KMT2A (0.62) | SLC18A3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL21074400 | 0.72 | HRH3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029189-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | HRH3, HRH4, HRH1 | SLC18A3 115/4885MEN1 1865/4885KMT2A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.